ArticleESC heart failure2020
Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure.
Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 29 citations in OpenAlex.
- Effects of heart failure pharmacotherapy on natriuresis and diuresis: A narrative review.Heart failure reviews · 2026Review
- Device therapies in cardiorenal syndrome: an expert review.ESC heart failure · 2026Review
- Expression profile of apolipoproteins (APOE) and endothelin-1 (ET-1) genes in ischemic heart disease.BMC cardiovascular disorders · 2026Article
- Urinary potassium/urinary creatinine ratio in outpatients with heart failure: factors associated and prognostic implications.Scientific reports · 2026Article
- Adipokine profile in acute heart failure: associations with natriuretic response and prognosis.ESC heart failure · 2026Observational
- Cumulative Serum Endothelin-1 and Endothelin-3 Level Predicts 1-year Adverse Cardiac Events after ST-Elevation Acute Myocardial Infarction.The International journal of angiology : official publication of the International College of Angiology, Inc · 2026Article
- Evaluation of Body Position Association with Diuretic Response and Neurohormonal Activation in Patients with Acutely Decompensated Heart Failure.Biomedicines · 2026Article
- Endothelin-2 and Its Association with Uric Acid Levels and Systemic Inflammation: Relevance to Chronic Kidney Disease Progression.International journal of molecular sciences · 2026Article
- Novel blood biomarkers for heart failure mortality: mechanistic pathways, aging biology, and risk stratification.Frontiers in cardiovascular medicine · 2026Review
- Urinary markers in heart failure - types, timing and thresholds. European Journal of Heart Failure expert consensus document.European journal of heart failure · 2025Review
- Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure.Korean circulation journal · 2025Article
- Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).Heart failure reviews · 2025Review
- Urine chloride trajectory and relationship with diuretic response in acute heart failure.ESC heart failure · 2025Article
- Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions.Cardiac failure review · 2025Review
- Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients.American journal of hypertension · 2024Article
- Loop diuretics in heart failure: The objective markers to guide the therapy are needed.ESC heart failure · 2024Article
- Review
- Hemorrhagic Fever with Renal Syndrome Patients Exhibit Increased Levels of Lipocalin-2, Endothelin-1 and NT-proBNP.Life (Basel, Switzerland) · 2023Article
- Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?Diagnostics (Basel, Switzerland) · 2023Review
- Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.Circulation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 5 countries.
Funding
Abstract
aimsEndothelin-1 (ET-1) is a potent vasoconstrictor, which regulates renal and vascular function. We aimed to relate plasma levels of ET-1 with the clinical picture and outcomes in acute heart failure (AHF). METHODS AND
resultsWe studied 113 patients with AHF [mean age 65 ± 13 (years), median (upper and lower quartiles) N-terminal pro-B-type natriuretic peptide, 5422 (2689; 8582) (pg/mL)], in whom plasma levels of ET-1 were serially measured at admission (10.8 ± 5.2), Day 1 (9.5 ± 3.4), and Day 2 (8.9 ± 3.8) (pg/mL). The population was divided into tertiles across baseline ET-1 levels. Patients in the highest ET-1 tertile had predominant clinical signs of peripheral congestion; however, no difference was observed in pulmonary congestion and severity of dyspnoea. They also presented lower spot urine sodium at admission (75 ± 35 vs. 99 ± 43 vs. 108 ± 30), 6 h (84 ± 34 vs. 106 ± 43 vs. 106 ± 35), and Day 1 (75 ± 38 vs. 96 ± 36 vs. 100 ± 35) (mmol/L), when compared with the second and first tertile, respectively (all P < 0.05); furthermore, they received higher doses of intravenous furosemide from Day 2 and had longer intravenous diuretics, as median switch to oral furosemide was 4 (3; 4) vs. 3 (2; 4) vs. 2 (2; 3) (days), respectively, P < 0.05. There was no difference in serum creatinine, urea, and renal injury biomarkers (kidney injury molecule-1, serum cystatin C, and urine neutrophil gelatinase-associated lipocalin) between the ET-1 tertiles. Higher values of ET-1 measured at each time point were related with a higher risk of 1 year mortality.
conclusionsElevation of ET-1 is related to clinical signs of peripheral congestion, low urine sodium excretion, and poor outcome in AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.